Around 30% of patients with schizophrenia show an inadequate response to antipsychotics—
ie, treatment resistance. Neuroimaging studies can help to uncover the underlying …

Background Recent developments in neuroimaging have advanced the understanding of
biological mechanisms underlying schizophrenia. However, neuroimaging correlates of …

Abstract Treatment resistant schizophrenia (TRS) refers to the significant proportion of
schizophrenia patients who continue to have symptoms and poor outcomes despite …

Studies that have used structural magnetic resonance imaging (MRI) suggest that
individuals with psychoses have brain alterations, particularly in frontal and temporal …

Background Schizophrenia is a highly heterogeneous disorder, and around a third of
patients are treatment-resistant. The only evidence-based treatment for these patients is …

Clozapine alleviates the symptoms of a significant proportion of treatment-resistant
schizophrenic patients. Previous studies suggest that the response to clozapine may be …

Antipsychotic treatment resistance affects up to a third of individuals with schizophrenia. Of
those affected, 70–84% are reported to be treatment resistant from the outset. This raises the …

Treatment-resistant symptoms occur in about a third of patients with schizophrenia and are
associated with a substantial reduction in their quality of life. The development of new …

Background Identification of patients at high risk of treatment-resistant schizophrenia at the
time of schizophrenia diagnosis would be of great clinical benefit in minimising the delay to …

Abstract Treatment-resistant schizophrenia (TRS), the persistence of positive symptoms
despite≥ 2 trials of adequate dose and duration of antipsychotic medication with …